Advance Search
LIU Xiaohong, LI Mei, WANG Fengyun, SI Yuchen, DU Xiaoli, SHI Liangliang, SHAO Haiou, CHEN Li, ZHANG Hongyan. Effect of modified Qiankun Yudan Decoction combined with leuprorelin acetate on serum carbohydrate antigen 125 and recurrence rate in patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 133-137. DOI: 10.7619/jcmp.20231988
Citation: LIU Xiaohong, LI Mei, WANG Fengyun, SI Yuchen, DU Xiaoli, SHI Liangliang, SHAO Haiou, CHEN Li, ZHANG Hongyan. Effect of modified Qiankun Yudan Decoction combined with leuprorelin acetate on serum carbohydrate antigen 125 and recurrence rate in patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 133-137. DOI: 10.7619/jcmp.20231988
shu

Effect of modified Qiankun Yudan Decoction combined with leuprorelin acetate on serum carbohydrate antigen 125 and recurrence rate in patients with adenomyosis

  • 1.

    the Second Department of Gynecology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei, 061000

  • 2.

    Department of Gynecology, Shijiazhuang Hospital of Traditional Chinese Medicine, Shijiazhuang, Hebei, 050000

More Information
  • Received Date: June 20, 2023
  • Revised Date: August 11, 2023
  • Available Online: October 08, 2023
    Graphical Abstract
    • Abstract
  • Objective 

    To analyze the efficacy of modified Qiankun Yudan Decoction combined with leuprorelin acetate in the treatment of patients with adenomyosis (AM) and its effect on serum carbohydrate antigen 125 (CA125) level and recurrence rate.

    Methods 

    A total of 120 patients with AM were randomly divided into control group (treated with leuprorelin acetate) and experimental group (treated with modified Qiankun Yudan Decoction on the basis of control group), with 60 cases in each group. Efficacy, the traditional Chinese medicine (TCM) syndrome score, dysmenorrhea score, serum CA125 level, uterine volume, occurrence of adverse reactions and recurrence rate were compared between the two groups.

    Results 

    The total effective rate in the experimental group was 95.00%, which was significantly higher than 80.00% in the control group (P < 0.05). After 3 and 6 months of treatment, the TCM syndrome score and dysmenorrhea score in both groups were significantly lower than those before treatment, and the scores in the experimental group were significantly lower than those in the control group (P < 0.05). After 3 and 6 months of treatment, serum CA125 and uterine volume in both groups were significantly lower or smaller than those before treatment, and the two indicators in the experimental group were significantly lower or shorter than those in the control group (P < 0.05). The total incidence rate of adverse reactions in the experimental group was 1.67%, which was significantly lower than 11.67% in the control group (P < 0.05). At the time point of follow-up to 3 months after the treatment, the experimental group had no recurrence cases, and the recurrence rate of control group was 5.00%, but there was no significant difference between two groups (P>0.05); at the time point of follow-up to 6 months after treatment, the recurrence rate was 1.67% in the experimental group, which was significantly lower than 13.33% in the control group (P < 0.05).

    Conclusion 

    Modified Qiankun Yudan Decoction combined with leuprorelin acetate can enhance the therapeutic efficacy in patients with AM, alleviate the TCM syndrome and dysmenorrhea symptoms, perform a good regulation effect on serum CA125, reduce the uterine volume, relieve the gastrointestinal discomfort and liver injury, and reduce the recurrence rate.

    • FullText(HTML)
    • References (22)
  • [1]
    朱梦赟, 陆启滨. 陆启滨治疗子宫腺肌症痛经经验[J]. 中华中医药杂志, 2019, 34(6): 2510-2513. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201906045.htm
    [2]
    沈雪, 段华. 子宫腺肌病病因及发病机制研究新观点[J]. 中国计划生育和妇产科, 2019, 11(4): 3-6. https://www.cnki.com.cn/Article/CJFDTOTAL-JHFC201904001.htm
    [3]
    关琼, 杨爱玉, 吴绪峰. 子宫腺肌病患者在醋酸亮丙瑞林基础上联合左炔诺孕酮宫内节育系统或地诺孕素治疗的效果比较[J]. 中国医药, 2023, 18(1): 86-90. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYG202301020.htm
    [4]
    程文秀, 郁悦, 刁翰林, 等. 中医体质学说在子宫腺肌病防治方面的应用研究[J]. 现代中医临床, 2021, 28(1): 69-72. doi: 10.3969/j.issn.2095-6606.2021.01.015
    [5]
    卢利霞, 边文会. 中西医治疗子宫腺肌病研究进展[J]. 河北中医药学报, 2019, 34(3): 54-58. https://www.cnki.com.cn/Article/CJFDTOTAL-HZYX201903018.htm
    [6]
    陈乙菲, 隋殿军. 血府逐瘀汤在不同系统疾病中的作用机制研究进展[J]. 吉林中医药, 2020, 40(5): 693-696. doi: 10.13463/j.cnki.jlzyy.2020.05.036
    [7]
    徐丛剑, 华克勤. 实用妇产科学[M]. 4版. 北京: 人民卫生出版社, 2018: 1-32.
    [8]
    谈勇. 中医妇科学[M]. 4版. 北京: 中国中医药出版社, 2016: 5-34.
    [9]
    商洪才, 王保和, 张伯礼. 中药新药证候及疗效评价[J]. 中药新药与临床药理, 2004, 15(5): 365-368. doi: 10.3321/j.issn:1003-9783.2004.05.024
    [10]
    子宫腺肌病伴不孕症诊疗中国专家共识编写组. 子宫腺肌病伴不孕症诊疗中国专家共识[J]. 中华生殖与避孕杂志, 2021, 41(4): 287-295. doi: 10.3760/cma.j.cn101441-20200222-00078
    [11]
    梁潇, 段彦苍, 宋亚静, 等. 基于文献研究与专家共识法的原发性痛经中医证候研究[J]. 中国中医药信息杂志, 2020, 27(2): 73-78. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202002016.htm
    [12]
    石一复. 有关子宫腺肌症一些问题的商榷[J]. 中国计划生育和妇产科, 2018, 10(1): 3-6. https://www.cnki.com.cn/Article/CJFDTOTAL-JHFC201801002.htm
    [13]
    沈姣梅. 左炔诺孕酮宫内缓释系统联合鳖甲煎丸对子宫腺肌症的治疗效果[J]. 贵州医科大学学报, 2021, 46(5): 616-620. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYB202105021.htm
    [14]
    洪莲, 陈旭. 超声引导下射频消融治疗子宫腺肌症疗效及对血清CA125的影响[J]. 现代中西医结合杂志, 2019, 28(23): 2566-2569. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH201923015.htm
    [15]
    李蕴微, 刘玉婷, 王姝, 等. 子宫腺肌病患者的血清CA125水平及其影响因素分析[J]. 中华妇产科杂志, 2019, 54(2): 110-113.
    [16]
    魏华莉, 牛秀敏, 王红霞. 注射用醋酸亮丙瑞林微球联合左炔诺孕酮宫内释放系统治疗子宫腺肌病患者的临床疗效[J]. 医学临床研究, 2019, 36(9): 1736-1738, 1741. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMYX202212017.htm
    [17]
    李亚敏, 焦惠霞, 苏健. 田淑霄教授从脾论治子宫腺肌症继发痛经经验荟萃[J]. 四川中医, 2015, 33(8): 10-11. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZY201508006.htm
    [18]
    侯爱贞, 王利平, 杜鹃, 等. 理冲汤联合生化汤颗粒治疗气虚血瘀型子宫腺肌病的效果及对机体卵巢功能的影响[J]. 实用医学杂志, 2023, 39(7): 910-913. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ202307021.htm
    [19]
    陈彩霞, 赵海云, 毛福兰, 等. 自拟温阳活血汤联合孕三烯酮胶囊治疗子宫腺肌病痛经临床研究[J]. 国际中医中药杂志, 2020, 42(9): 861-865.
    [20]
    张晓沁, 杨红. 补肾活血加减方治疗子宫腺肌病月经过多的疗效及对月经、卵巢功能改善和血清CA125、LH、FSH水平的影响[J]. 四川中医, 2019, 37(3): 173-175. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZY201903062.htm
    [21]
    郭赟, 包东明. Embosphere微球子宫动脉栓塞对重症子宫腺肌病患者月经恢复及血清性激素的影响[J]. 中国妇产科临床杂志, 2021, 22(5): 480-482. https://www.cnki.com.cn/Article/CJFDTOTAL-FKLC202105011.htm
    [22]
    陈燕, 石家振, 赵霞. 行气化瘀消癥汤联合孕三烯酮治疗子宫腺肌病的临床观察[J]. 中国中医药科技, 2021, 28(5): 830-831. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYY202105067.htm
    • Related Articles

  • Related Articles

    [1]SHAO Zhongxin, LI Shiying. Effect of propofol regulating macrophage polarization on airway inflammatory response and Toll-like receptor 4-NOD-like receptor protein 3 pathway in mice with bronchial asthma[J]. Journal of Clinical Medicine in Practice, 2025, 29(6): 13-19. DOI: 10.7619/jcmp.20245587
    [2]YU Jingjing, HU Meng, Xierenguli ALIMU, ZHANG Man, QU Jianhua. Experimental study on treatment of relapsed and refractory acute myeloid leukemia with DNA methyltransferase 1 inhibitor combined with extracellular signal-regulated kinase 1, homeodomain-interacting protein kinase 2, and glycogen synthase kinase 3β inhibitors[J]. Journal of Clinical Medicine in Practice, 2025, 29(5): 26-30, 35. DOI: 10.7619/jcmp.20242914
    [3]GUO Taotao, WANG Jingjing, LIU Cui, YU Hui, XIE Wenyao, ZHANG Bin, JIANG Lili. Effect of dienogest in improvement of endometriosis and its mechanism[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 108-113. DOI: 10.7619/jcmp.20244000
    [4]WUMAIERJIANG Aishanjiang, AIMAITI Adilijiang, WU Xuan, WUBULIHASIMU Gulinigeer, YANG Shu. Impact and mechanism of NOD-like receptor thermal protein domain-associated protein 3 on pathological features and inflammatory response in a rat model of hemorrhoids[J]. Journal of Clinical Medicine in Practice, 2025, 29(2): 102-107. DOI: 10.7619/jcmp.20244142
    [5]XING Xiaoyan, LIU Lirui, BAI Long, JI Yanna, HE Xiaolong. Correlations of serum NLRC3 and ECM1 expression with acute respiratory distress syndrome in sepsis patients[J]. Journal of Clinical Medicine in Practice, 2024, 28(21): 38-42, 47. DOI: 10.7619/jcmp.20242473
    [6]LAN Youling, LI Tianfa, ZHAN Yatong, CHEN Yan'e, GUAN Fuqing, YANG Yang. Effect of adjuvant therapy of Shenfu Injection on NOD-like receptor protein 3/cysteine-aspartic acid-specific protease 1 mediated pyroptosis signaling pathway and inflammatory factor levels in rats with acute myocardial infarction[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 3-8, 13. DOI: 10.7619/jcmp.20240909
    [7]HUANG Yan, LIANG Yumei, FENG Yanni, YANG Songmei. The relationships of the levels of receptor-interacting protein kinase 3 and mixed lineage kinase domain-like protein in peripheral blood with the severity of necrotizing enterocolitis in newborns[J]. Journal of Clinical Medicine in Practice, 2024, 28(1): 62-67. DOI: 10.7619/jcmp.20232431
    [8]GAO Shuyue, ZHAO Feiyu, FAN Runjia, CHENG Jiamin, QIAN Niansong. Clinical application status of T cell immunoglobulin and mucin domain-containing protein 3 and its monoclonal antibody in tumor[J]. Journal of Clinical Medicine in Practice, 2023, 27(24): 132-137. DOI: 10.7619/jcmp.20232215
    [9]WANG Haoran, FENG Qin, ZHANG Zhengang, GAO Yang, LI Rujun. Clinical efficacy of Shexiang Tongxin Dropping Pill combined with conventional therapy in patients with myocardial ischemia reperfusion injury[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 76-80. DOI: 10.7619/jcmp.20231020
    [10]XU Dongrui, WANG Xiaolong, MA Wenchao, LIU Tongxiang, DONG Yuanbao, YIN Lijuan. Effect of nucleotide binding oligomerization domain-like receptor protein 3 inflammasome on in-stent restenosis after coronary stent implantation[J]. Journal of Clinical Medicine in Practice, 2021, 25(19): 16-19. DOI: 10.7619/jcmp.20211930

  • Cited by

    Periodical cited type(15)

    1. 高淑彦，赵瑞芳，李文静，刘倩楠，沈青青. 阿托伐他汀钙联合环磷腺苷与托拉塞米治疗老年慢性心功能不全的疗效及对血清BNP、Gal-3、sICAM-1水平的影响. 临床和实验医学杂志. 2025(01): 5-9 .
    2. 谢兆莉，张耀堂，苏书艳. 环磷腺苷葡胺联合新四联方案治疗慢性心力衰竭的疗效及对心功能指标的影响. 临床合理用药. 2025(08): 16-19 .
    3. 田茂婷，朱应华. 沙库巴曲缬沙坦联合环磷腺苷葡胺对老年慢性心力衰竭患者心率变异性及心功能的影响. 中外医疗. 2024(03): 104-107 .
    4. 李树云，刘爱环，郝玲. 卡托普利与左西孟旦共同治疗慢性心力衰竭的效果. 慢性病学杂志. 2024(05): 755-758 .
    5. 王坤，孔令才，许林艳，王磊. 心脉隆注射液联合环磷腺苷葡胺治疗高龄慢性心力衰竭效果分析. 世界复合医学(中英文). 2024(02): 9-12 .
    6. 王斌. 注射用环磷腺苷葡胺联合复窦合剂对急性心肌梗死后心律失常的应用效果及对QRS波时限、左室射血分数水平影响. 中华养生保健. 2024(16): 53-56 .
    7. 葛梦芸. 氧化樟脑注射液联合环磷腺苷葡胺治疗心力衰竭的临床疗效分析. 北方药学. 2024(11): 149-151 .
    8. 应璇，贾彩乐，何好权，陈舒，刘俊. 麝香通心滴丸联合沙库巴曲缬沙坦对慢性心力衰竭患者的临床疗效观察. 浙江医学. 2023(06): 617-620 .
    9. 窦东锋，刘洪光，张丽芬. 单硝酸异山梨酯联合培哚普利叔丁胺治疗老年慢性心力衰竭患者的疗效. 国际医药卫生导报. 2023(09): 1276-1280 .
    10. 赵智慧，宋雨，吴东彬，王娇娇. 冠心宁联合单硝酸异山梨酯治疗慢性心力衰竭患者临床疗效及对心功能的影响. 药学研究. 2023(05): 348-351 .
    11. 祖建杰. 卡维地洛联合硝酸异山梨酯在治疗重症心力衰竭中的疗效及其对血清CXCL10和CXCL12水平的影响. 检验医学与临床. 2023(20): 3033-3036 .
    12. 刘长英. 左西孟旦与环磷腺苷葡胺联合治疗顽固性心力衰竭的临床观察. 大医生. 2023(22): 56-58 .
    13. 郭城楠. 慢性心力衰竭药物治疗临床研究进展. 天津药学. 2022(04): 64-69 .
    14. 韩勇，郭艳涛. 单硝酸异山梨酯联合培哚普利叔丁胺治疗慢性心力衰竭的疗效. 深圳中西医结合杂志. 2022(15): 96-99 .
    15. 朱明. 环磷腺苷葡胺对老年慢性心力衰竭治疗效果. 现代诊断与治疗. 2022(23): 3533-3536 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (119) PDF downloads (2) Cited by(17)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return